Spinraza-Zolgensma Combination Well-tolerated in Children with SMA Type 1, Study Shows

Spinraza-Zolgensma Combination Well-tolerated in Children with SMA Type 1, Study Shows

Combining Spinraza (nusinersen) with the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) is generally well-tolerated and sustains motor improvements in children with spinal muscular atrophy (SMA) type 1, according to a case series study. The data, which...
Lake-Breaking SMA Treatment Insights You May Have Missed in February

Lake-Breaking SMA Treatment Insights You May Have Missed in February

February wrapped up with a surge of data on SMA, including novel investigations into how combinatorial therapies may provide new advantages to those with the disease. More information on how nusinersen impacts patients has also become available, as have new findings...
SMA HCP News December Round-up: Spinal Cord Hypoxia, Scoliosis Surgery & More

SMA HCP News December Round-up: Spinal Cord Hypoxia, Scoliosis Surgery & More

Regulators continue to review SMA drugs and consider policies related to newborn screening while new data emerge related to the mechanisms underlying the disease, as well as those concerning management and treatment.  Here is a roundup of some of the latest news and...